Alcyomics
Daniel Bull is a scientist currently employed at Alcyomics since October 2023. Previously, Daniel worked at Helena Biosciences as a Research and Development Scientist from March 2023 to October 2023. Daniel also served as a Senior Bioprocessing Scientist at Leica Biosystems, holding the position for a significant duration. Daniel holds a Bachelor of Science degree in Biomedical Science from the University of Sunderland, earned between June 2015 and September 2017.
This person is not in any teams
Alcyomics
Alcyomics is a specialist clinical research organization (CRO) supporting the pharmaceutical, biotechnology, and cosmetics industries. We offer full assay services and technical consultancy in immuno-toxicology. This is underpinned by our patented human in vitro skin assay platform, Skimune®, which provides highly sensitive detection of adverse immune reactions for pre-clinical testing of small and large molecule drugs, monoclonal antibodies, cellular therapies, cosmetic compounds etc. plus many more. Further to our immunotoxicity platforms we also specialise in 3D assay design, optimisation and validation. We have a number of 3D assays in-house such as; - Autologous skin model, Skimune 3D, for high-throughput immunotoxicity testing. - 3D innervated skin model is based in a 96-well scaffold system and has been specifically validated to detect peripheral toxicity against monoclonal antibodies and chemical insults. - Bioprinted osteo-chondral model incorporates the complex environment present in osteoarthritis. - Autologous atopic dermatitis models incorporating immune cellular function to assess compound function, efficacy and toxicity. From our state of the art facilities based within the custom built Biosphere labs in Newcastle-upon-Tyne, UK, we provide assured, experienced, professional assay support and consultancy to local, national, and international clients. Our Mission at Alcyomics is to provide robust in vitro human assays to the pharmaceutical, biotechnology, chemical and cosmetic industries that enable early detection of adverse immune reactions, reducing risk and cost in the development of drugs and compounds. www.alcyomics.com